about
Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAsPrognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality.Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and BakAssociation of acute myeloid leukemia's most immature phenotype with risk groups and outcomesRecent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.Role of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes.ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.Cancer mortality predictions for 2017 in Latin America.Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients
P2860
Q28071427-53514DB7-5707-4100-8883-08B18E6A842DQ35348105-16F9059C-EE9D-4657-A105-69543F380B14Q36376119-B8A634B8-475C-46B9-8710-64DA228658C9Q36642752-6F0FB33D-8EBE-43F1-9311-CBB232FBD916Q37095358-A396C38E-8687-452E-87A2-5B2A32A31D91Q37216232-2D3ABAF6-A5BC-4809-A2BE-F7E8BAEE2194Q38122703-76D0656E-62C5-4DBF-B663-25D0B9163B44Q39202260-51F1100D-AEBA-42EF-B9C4-EE2D92DC4E30Q40852245-B595E0EC-48FA-4A79-8962-F06C5E498C15Q47694454-7609014A-01B0-4DC0-8AFC-509D96F38CC9Q52668213-7292D26B-169B-4536-886E-A651CF20CD69Q52873870-3C11FE4C-A9AF-4F08-A414-0EE010005E1CQ56974946-B3BD96FF-7E22-4AFC-BD99-C7BBABFF6B5F
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
How to manage high-risk acute myeloid leukemia.
@en
How to manage high-risk acute myeloid leukemia.
@nl
type
label
How to manage high-risk acute myeloid leukemia.
@en
How to manage high-risk acute myeloid leukemia.
@nl
prefLabel
How to manage high-risk acute myeloid leukemia.
@en
How to manage high-risk acute myeloid leukemia.
@nl
P2860
P356
P1433
P1476
How to manage high-risk acute myeloid leukemia.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2011.317
P577
2011-11-25T00:00:00Z